A NON-INTERVENTIONAL, MULTICENTER, MULTIPLE COHORT STUDY INVESTIGATING THE OUTCOMES AND SAFETY OF ATEZOLIZUMAB UNDER REAL- WORLDCONDITIONS IN PATIENTS TREATED IN ROUTINE CLINICAL PRACTICE - IMreal

F HoffmanLa Roche Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年4月29日

试验速览

暂无简介。

•1. Confirmed diagnosis for which atezolizumab is locally approved
•2. Patient is prescribed atezolizumab therapy for the first time
•3. Decision to prescribe atezolizumab must be made and documented prior to inclusion into the study and must follow local clinical practice
•4. Patient is 18 years or older at the index date
•5. Patient has signed an informed consent form
•6. Initiation of atezolizumab is not more than 28 days before signing informed consent. In countries where enrollment is only allowed after starting treatment, enrollment must be preceded by the administration of the first cycle of atezolizumab

•1. Treatment with atezolizumab for an indication that is not included in the study cohorts
•2. Concomitant anti-cancer therapy at the time of starting atezolizumab on the index date, as per locally approved SmPC
•3. Treatment with atezolizumab as part of a clinical trial or as compassionate use as part of an access or compassionate use program

发起方

F HoffmanLa Roche Ltd